The offering, priced at a combined $0.34 per share and accompanying warrants, is expected to close on or about July 1, 2026, subject to customary closing conditions. H.C. Wainwright & Co. is serving as the exclusive placement agent for the transaction. The capital injection is intended to bolster the company's working capital and support the ongoing development of its proprietary rhCollagen-based medical technologies, which focus on 3D bioprinting and tissue repair.

Under the terms of the agreement, both series of warrants become exercisable following shareholder approval. Series A warrants expire two years after the registration statement becomes effective, while series B warrants carry a five-year lifespan. CollPlant has committed to filing a registration statement with the U.S. Securities and Exchange Commission to facilitate the resale of the shares and those underlying the warrants.